| Dramatical Response to “Low Dose Ultra-Slow Infusion” of Alteplase for Massive Mitral Mechanical Valve Thrombosis | Fuatcan BALABAN, Metin ÇOKSEVİM, Mahmut ŞAHİN, Serkan YÜKSEL | 6–7 |
| Focus on Micro RNAs and Pulmonary Hypertension | Çetin EROL | 345–345 |
| Overview of Current Strategies Aiming at Improving Response to Cardiac Resynchronization Therapy | Kerim ESENBOĞA, Emr BASKOVSKİ, Yakup Yunus YAMANTÜRK, Başar CANDEMİR | 346–353 |
| Does Dexmedetomidine Reduce the Risk of Atrial Fibrillation and Stroke After Adult Cardiac Surgery? A Systematic Review and Meta-analysis of Randomized Controlled Trials | Cuicui JING,Lixue LIN,Tong ZHOU,Yi Liang LI,Yi FU,Meng Qi GAO | 354–365 |
| Functional Significance of Cardiac Rehabilitation-Regulated Expression of Circulating MicroRNA-423-5p in Hypertensive Patients with Heart Failure with a Moderately Reduced Ejection Fraction | Ying HUANG,Yun ZHANG,Wenzheng NONG,Biyong LAN,Dingmin ZHANG | 366–372 |
| MiRNA-615-3p Alleviates Oxidative Stress Injury of Human Cardiomyocytes Via PI3K/Akt Signaling by Targeting MEF2A | Kun YU, Dongying ZHANG, Gang ZHANG, Xiwen ZHANG, Aixia JIANG | 373–381 |
| Impact of the Total Ischemia Time on No-Reflow Phenomenon in Patients with ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention | Mohamed KHALFALLAH,Amany ALLAITHY,Dina A. MARİA | 382–387 |
| Kynurenine–PARP-1 Link Mediated by MicroRNA 210 May Be Dysregulated in Pulmonary Hypertension | Alperen Emre AKGÜN,Yalın Tolga YAYLALI,Mücahit SEÇME,Yavuz DODURGA,Hande ŞENOL | 388–393 |
| Pulmonary Endarterectomy in Patients with Antiphospholipid Syndrome-Associated Chronic Thromboembolic Pulmonary Hypertension | Şehnaz OLGUN YILDIZELİ, Atakan ERKILINÇ, Derya KOCAKAYA, Serpil TAŞ, Arzu ANTAL, Nevsun İNANÇ, Haner DİRESKENELİ, Bülent MUTLU, Bedrettin YILDIZELİ, Mehmed YANARTAŞ, Fatma ALİBAZ ÖNER, Ali Fuad DURUSOY, Kübra YILDIZ | 394–400 |
| Enhanced External Counterpulsation Effects on Venous Leg Symptoms | Ertan YETKİN, Hasan TURHAN, Bilal ÇUĞLAN | 401–406 |
|